Special focus is placed on the potential use of liquid biopsy in the optimization of decision making in BC patient management and on the role of multiple microRNAs (miRNAs) as molecular predictors of treatment response/resistance to CDK4/6 inhibitors. The gene discussed is CDK4; the disease is breast cancer.